FDA accepts supplemental application for Zoryve foam for scalp, body psoriasis

The FDA has accepted Arcutis Biotherapeutics’ supplemental new drug application for Zoryve foam 0.3% for the treatment of scalp and body psoriasis in adults and adolescents aged 12 years and older, the company announced in a press release.
Zoryve (roflumilast) foam 0.3% in this indication has received a Prescription Drug User Fee Act date of May 22, 2025.
“Zoryve foam, if approved, would represent a truly meaningful innovation for millions of people with scalp and body psoriasis whose symptoms have not been adequately addressed by existing treatments,” Frank Watanabe,

The FDA has accepted Arcutis Biotherapeutics’ supplemental new drug application for Zoryve foam 0.3% for the treatment of scalp and body psoriasis in adults and adolescents aged 12 years and older, the company announced in a press release.
Zoryve (roflumilast) foam 0.3% in this indication has received a Prescription Drug User Fee Act date of May 22, 2025.
“Zoryve foam, if approved, would represent a truly meaningful innovation for millions of people with scalp and body psoriasis whose symptoms have not been adequately addressed by existing treatments,” Frank Watanabe,